123 related articles for article (PubMed ID: 8001867)
1. Evaluation of plasminogen activators and plasminogen activator inhibitors in plasma and amniotic fluid in pregnancies complicated with intrauterine fetal growth retardation.
Gilabert J; Estellés A; Ayuso MJ; España F; Chirivella M; Grancha S; Micó JM; Aznar J
Gynecol Obstet Invest; 1994; 38(3):157-62. PubMed ID: 8001867
[TBL] [Abstract][Full Text] [Related]
2. Plasminogen activator inhibitors type 1 and type 2 and plasminogen activators in amniotic fluid during pregnancy.
Estellés A; Gilabert J; Andrés C; España F; Aznar J
Thromb Haemost; 1990 Oct; 64(2):281-5. PubMed ID: 2125378
[TBL] [Abstract][Full Text] [Related]
3. Fibrinolytic components in fetal membranes and amniotic fluid.
Watanabe T; Araki M; Mimuro J; Tamada T; Sakata Y
Am J Obstet Gynecol; 1993 Apr; 168(4):1283-9. PubMed ID: 7682753
[TBL] [Abstract][Full Text] [Related]
4. Coagulation and fibrinolytic parameters in normal pregnancy and in pregnancy complicated by intrauterine growth retardation.
Bellart J; Gilabert R; Fontcuberta J; Carreras E; Miralles RM; Cabero L
Am J Perinatol; 1998 Feb; 15(2):81-5. PubMed ID: 9514130
[TBL] [Abstract][Full Text] [Related]
5. Fibrinolytic parameters in normotensive pregnancy with intrauterine fetal growth retardation and in severe preeclampsia.
Estellés A; Gilabert J; España F; Aznar J; Galbis M
Am J Obstet Gynecol; 1991 Jul; 165(1):138-42. PubMed ID: 1906680
[TBL] [Abstract][Full Text] [Related]
6. Altered expression of plasminogen activator inhibitor type 1 in placentas from pregnant women with preeclampsia and/or intrauterine fetal growth retardation.
Estellés A; Gilabert J; Keeton M; Eguchi Y; Aznar J; Grancha S; Espña F; Loskutoff DJ; Schleef RR
Blood; 1994 Jul; 84(1):143-50. PubMed ID: 8018914
[TBL] [Abstract][Full Text] [Related]
7. Plasminogen activators, plasminogen activator inhibitors and markers of intravascular coagulation in pre-eclampsia.
Koh SC; Anandakumar C; Montan S; Ratnam SS
Gynecol Obstet Invest; 1993; 35(4):214-21. PubMed ID: 8330765
[TBL] [Abstract][Full Text] [Related]
8. Fibrinolysis during normal pregnancy and severe preeclampsia relationships between plasma levels of plasminogen activators and inhibitors.
Nakashima A; Kobayashi T; Terao T
Gynecol Obstet Invest; 1996; 42(2):95-101. PubMed ID: 8878712
[TBL] [Abstract][Full Text] [Related]
9. Abnormal expression of plasminogen activator inhibitors in patients with gestational trophoblastic disease.
Estellés A; Grancha S; Gilabert J; Thinnes T; Chirivella M; España F; Aznar J; Loskutoff DJ
Am J Pathol; 1996 Oct; 149(4):1229-39. PubMed ID: 8863672
[TBL] [Abstract][Full Text] [Related]
10. Decreased expression of PAI-2 mRNA and protein in pregnancies complicated with intrauterine fetal growth retardation.
Grancha S; Estellés A; Gilabert J; Chirivella M; España F; Aznar J
Thromb Haemost; 1996 Nov; 76(5):761-7. PubMed ID: 8950787
[TBL] [Abstract][Full Text] [Related]
11. Plasminogen activators and plasminogen activator inhibitors in blood and tumour fluids of patients with ovarian cancer.
Casslén B; Bossmar T; Lecander I; Astedt B
Eur J Cancer; 1994; 30A(9):1302-9. PubMed ID: 7999418
[TBL] [Abstract][Full Text] [Related]
12. Involvement of fibrinolytic factors in mid trimester amniotic fluid with development of severe early-onset preeclampsia.
Adachi T; Nakabayashi M; Sakura M; Ando K
Semin Thromb Hemost; 1999; 25(5):447-50. PubMed ID: 10625200
[TBL] [Abstract][Full Text] [Related]
13. Plasminogen activator of urokinase type and its inhibitor of placental type in hypertensive pregnancies and in intrauterine growth retardation: possible markers of placental function.
Lindoff C; Astedt B
Am J Obstet Gynecol; 1994 Jul; 171(1):60-4. PubMed ID: 8030735
[TBL] [Abstract][Full Text] [Related]
14. Complex congenital malformations and the impact of the plasminogen activator system and beta-hCG in amniotic fluid.
Verkleij-Hagoort AC; Ursem NT; Hop WC; Geurts-Moespot A; Steegers EA; Sweep FC; Steegers-Theunissen RP
Eur J Obstet Gynecol Reprod Biol; 2007 Nov; 135(1):47-52. PubMed ID: 17141398
[TBL] [Abstract][Full Text] [Related]
15. Uteroplacental hemostasis in intrauterine fetal growth retardation.
Sheppard BL; Bonnar J
Semin Thromb Hemost; 1999; 25(5):443-6. PubMed ID: 10625199
[TBL] [Abstract][Full Text] [Related]
16. Influence of delivery on plasminogen activator inhibitor activity.
Koelbl H; Kirchheimer J; Tatra G
J Perinat Med; 1989; 17(2):107-11. PubMed ID: 2681664
[TBL] [Abstract][Full Text] [Related]
17. Significance of the plasminogen activator inhibitor of placental type (PAI-2) in pregnancy.
Astedt B; Lindoff C; Lecander I
Semin Thromb Hemost; 1998; 24(5):431-5. PubMed ID: 9834009
[TBL] [Abstract][Full Text] [Related]
18. Plasminogen activator system in oral squamous cell carcinoma.
Baker EA; Leaper DJ; Hayter JP; Dickenson AJ
Br J Oral Maxillofac Surg; 2007 Dec; 45(8):623-7. PubMed ID: 17590247
[TBL] [Abstract][Full Text] [Related]
19. Plasminogen activators and their inhibitors in leukemic cell homogenates.
Wada H; Kumeda Y; Ogasawara Z; Ohiwa M; Kaneko T; Tamaki S; Ohno T; Kageyama S; Kobayashi T; Deguchi K
Am J Hematol; 1993 Feb; 42(2):166-70. PubMed ID: 8438877
[TBL] [Abstract][Full Text] [Related]
20. Increased human placental growth hormone at midtrimester pregnancies may be an index of intrauterine growth retardation related to preeclampsia.
Papadopoulou E; Sifakis S; Giahnakis E; Fragouli Y; Karkavitsas N; Koumantakis E; Kalmanti M
Growth Horm IGF Res; 2006; 16(5-6):290-6. PubMed ID: 16996762
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
